Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity
Identifieur interne : 003138 ( Istex/Corpus ); précédent : 003137; suivant : 003139Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity
Auteurs : Cathy Chuang ; Anne Constantino ; Casilda Balmaceda ; David Eidelberg ; Steven J. FruchtSource :
- Movement Disorders [ 0885-3185 ] ; 2003-03.
English descriptors
- KwdEn :
Abstract
Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10344
Links to Exploration step
ISTEX:8A274E6F221962934BC1966811DBBDDEAB2FE63ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title><author><name sortKey="Chuang, Cathy" sort="Chuang, Cathy" uniqKey="Chuang C" first="Cathy" last="Chuang">Cathy Chuang</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Constantino, Anne" sort="Constantino, Anne" uniqKey="Constantino A" first="Anne" last="Constantino">Anne Constantino</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Balmaceda, Casilda" sort="Balmaceda, Casilda" uniqKey="Balmaceda C" first="Casilda" last="Balmaceda">Casilda Balmaceda</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>North‐Shore University Hospital, Manhasset, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8A274E6F221962934BC1966811DBBDDEAB2FE63E</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10344</idno><idno type="url">https://api.istex.fr/document/8A274E6F221962934BC1966811DBBDDEAB2FE63E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003138</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title><author><name sortKey="Chuang, Cathy" sort="Chuang, Cathy" uniqKey="Chuang C" first="Cathy" last="Chuang">Cathy Chuang</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Constantino, Anne" sort="Constantino, Anne" uniqKey="Constantino A" first="Anne" last="Constantino">Anne Constantino</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Balmaceda, Casilda" sort="Balmaceda, Casilda" uniqKey="Balmaceda C" first="Casilda" last="Balmaceda">Casilda Balmaceda</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>North‐Shore University Hospital, Manhasset, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation><mods:affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003-03">2003-03</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="328">328</biblScope><biblScope unit="page" to="331">331</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8A274E6F221962934BC1966811DBBDDEAB2FE63E</idno><idno type="DOI">10.1002/mds.10344</idno><idno type="ArticleID">MDS10344</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>chemotherapy</term><term>levodopa</term><term>parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated. © 2002 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Cathy Chuang MD</name><affiliations><json:string>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Anne Constantino MD</name><affiliations><json:string>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Casilda Balmaceda MD</name><affiliations><json:string>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>David Eidelberg MD</name><affiliations><json:string>North‐Shore University Hospital, Manhasset, New York, USA</json:string></affiliations></json:item><json:item><name>Steven J. Frucht MD</name><affiliations><json:string>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>chemotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated. © 2002 Movement Disorder Society</abstract><qualityIndicators><score>3.757</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>698</abstractCharCount><pdfWordCount>2617</pdfWordCount><pdfCharCount>18319</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>95</abstractWordCount></qualityIndicators><title>Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title><genre><json:string>Serial article</json:string></genre><host><volume>18</volume><pages><total>4</total><last>331</last><first>328</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1002/mds.10344</json:string></doi><id>8A274E6F221962934BC1966811DBBDDEAB2FE63E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8A274E6F221962934BC1966811DBBDDEAB2FE63E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8A274E6F221962934BC1966811DBBDDEAB2FE63E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8A274E6F221962934BC1966811DBBDDEAB2FE63E/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2003</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title><author><persName><forename type="first">Cathy</forename><surname>Chuang</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Jacobi Medical Center, 1400 Pelham Parkway South, Room 2E17, Bronx, NY 10461</p></note><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Anne</forename><surname>Constantino</surname><roleName type="degree">MD</roleName></persName><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Casilda</forename><surname>Balmaceda</surname><roleName type="degree">MD</roleName></persName><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">David</forename><surname>Eidelberg</surname><roleName type="degree">MD</roleName></persName><affiliation>North‐Shore University Hospital, Manhasset, New York, USA</affiliation></author><author><persName><forename type="first">Steven J.</forename><surname>Frucht</surname><roleName type="degree">MD</roleName></persName><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003-03"></date><biblScope unit="vol">18</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="328">328</biblScope><biblScope unit="page" to="331">331</biblScope></imprint></monogr><idno type="istex">8A274E6F221962934BC1966811DBBDDEAB2FE63E</idno><idno type="DOI">10.1002/mds.10344</idno><idno type="ArticleID">MDS10344</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2003</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated. © 2002 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>parkinsonism</term></item><item><term>chemotherapy</term></item><item><term>levodopa</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-12-07">Received</change><change when="2002-08-26">Registration</change><change when="2003-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8A274E6F221962934BC1966811DBBDDEAB2FE63E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v18:3</doi><numberingGroup><numbering type="journalVolume" number="18">18</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2003-03">March 2003</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.10344</doi><idGroup><id type="unit" value="MDS10344"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2003 Movement Disorders Society</copyright><eventGroup><event type="manuscriptReceived" date="2001-12-07"></event><event type="manuscriptRevised" date="2002-05-23"></event><event type="manuscriptAccepted" date="2002-08-26"></event><event type="firstOnline" date="2002-10-28"></event><event type="publishedOnlineFinalForm" date="2003-02-28"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2002-10-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">328</numbering><numbering type="pageLast">331</numbering></numberingGroup><correspondenceTo>Jacobi Medical Center, 1400 Pelham Parkway South, Room 2E17, Bronx, NY 10461</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS10344.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="2221"></count></countGroup><titleGroup><title type="main" xml:lang="en">Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title><title type="short" xml:lang="en">Chemotherapy‐Induced Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Cathy</givenNames><familyName>Chuang</familyName><degrees>MD</degrees></personName><contactDetails><email>cathychuang@usa.net</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anne</givenNames><familyName>Constantino</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Casilda</givenNames><familyName>Balmaceda</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>David</givenNames><familyName>Eidelberg</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Steven J.</givenNames><familyName>Frucht</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>North‐Shore University Hospital, Manhasset, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">parkinsonism</keyword><keyword xml:id="kwd2">chemotherapy</keyword><keyword xml:id="kwd3">levodopa</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated. © 2002 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Chemotherapy‐Induced Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity</title></titleInfo><name type="personal"><namePart type="given">Cathy</namePart><namePart type="family">Chuang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation><description>Correspondence: Jacobi Medical Center, 1400 Pelham Parkway South, Room 2E17, Bronx, NY 10461</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anne</namePart><namePart type="family">Constantino</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Casilda</namePart><namePart type="family">Balmaceda</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Eidelberg</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>North‐Shore University Hospital, Manhasset, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Steven J.</namePart><namePart type="family">Frucht</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2003-03</dateIssued><dateCaptured encoding="w3cdtf">2001-12-07</dateCaptured><dateValid encoding="w3cdtf">2002-08-26</dateValid><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">17</extent><extent unit="words">2221</extent></physicalDescription><abstract lang="en">Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated. © 2002 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>parkinsonism</topic><topic>chemotherapy</topic><topic>levodopa</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>328</start><end>331</end><total>4</total></extent></part></relatedItem><identifier type="istex">8A274E6F221962934BC1966811DBBDDEAB2FE63E</identifier><identifier type="DOI">10.1002/mds.10344</identifier><identifier type="ArticleID">MDS10344</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2003 Movement Disorders Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003138 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003138 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8A274E6F221962934BC1966811DBBDDEAB2FE63E
|texte= Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity
}}
| This area was generated with Dilib version V0.6.23. |  |